Background. U.S. FDA labeling restricts 8-week treatment courses of ledipasvir/ sofosbuvir (LDV/SOF) to treatment-naïve, HCV-genotype 1, non-cirrhotic patients with baseline viral load (VL) < 6 million IU/mL. A large proportion of patients who meet this criteria continue to undergo longer treatment durations. The primary objective of this analysis was to compare sustained virologic response rates at 12 weeks after treatment (SVR12) among patients receiving 8 vs. 12 weeks of therapy in a real-world clinical setting. Our secondary objective was to quantify uptake of the 8-week regimen in eligible patients.
Methods. This was a single-center, retrospective study of HCV-infected patients prescribed LDV/SOF at ambulatory clinics associated with the University of Maryland Medical Center (UMMC) from May 2015 to May 2016. Data were obtained from the UMMC electronic medical record and outpatient pharmacy claims database. Comparison between groups were made using Chi-squared or Fisher's exact test for categorical variables and Student's t-test or Wilcoxon rank-sum for continuous variables.
Results. A total of 288 patients were included. Median age was 58 years; 62.8% were male; 81.9% were black. Patients who received 12 weeks of therapy were significantly more likely to have a cirrhosis diagnosis, higher mean fibrosis score, and HCV/ HIV-coinfection at baseline. SVR12 was achieved in 67 (95.7%) patients in the 8-week group vs. 138 (93.9%) in the 12 week group (P = 0.755). Amongst black patients, 168 (93.9%) achieved SVR12 compared with 36 (97.3%) non-black patients, (P = 0.944). Amongst HCV/HIV-coinfected patients, 89 (93.1%) achieved SVR12 compared with 67 (94.7%) without HCV/HIV-coinfection (P = 0.748). Overall, 40.6% (n = 117) met criteria for an 8-week treatment duration and 44% (n = 52) of those eligible patients received 8 weeks of therapy. The uptake rate of the 8-week treatment course was 44.4%.
Conclusion. Eight-week treatment duration of LDV/SOF was effective for treatment-naïve, non-cirrhotic, HCV-genotype 1 patients in this real-world setting. Race and HCV/HIV-coinfection did not significantly impact patients' ability to achieve SVR12. Increased uptake of the 8-week regimen will decrease costs of therapy for patients and payers without compromising outcomes.
Disclosures. All authors: No reported disclosures. October 5, 2017: 12:30 PM Background. Phase 3 trials evaluating direct-acting antivirals (DAA) consistently report high sustained virologic responses (SVR). The strict eligibility criteria applied to these studies may affect the reproducibility in clinical practice. It has been demonstrated that drug use generally does not affect SVR. This retrospective cohort study sought to estimate the proportion of patients followed in a tertiary addiction clinic that would meet eligibility criteria for clinical trials, if drug use was not considered as a rejection criteria.
Patients Followed in an Addiction
Methods. The sample population consists of patients with active HCV genotypes (GT) 1-3, seen at the clinic between 01/2013 and 09/2015. Information from clinical charts was retrieved to examine how participants would meet the eligibility criteria of 14 studies. Individual patient's data were compared with the studies' eligibility criteria.
Results. A total of 234 patients met the inclusion criteria (GT 1: 58.1%; GT 2: 8.5%, GT 3: 34.2%; experienced: 16.2%; cirrhotic: 14.5%) and 53% (124/234) of patients could have been included in at least one study. Table shows individual study results. The most inclusive study was COSMOS (31/49; 63%). The most frequent exclusion criteria were the presence of significant diseases (cardiac, pulmonary, hepatic, porphyria or other), contraindicated medication and haemoglobin level.
Conclusion. Even without considering drug use, only half of the patients of the addiction clinic would have been eligible for at least one study. This under-representation stems from strict eligibility criteria that promote a healthier population. Our study suggests that the DAA might prove less effective when administered to infected populations followed in specialized clinics for drug. Medicine, Melbourne University, Melbourne, Australia Session: 59. Hepatitis B and C in Varied Settings Thursday, October 5, 2017: 12:30 PM Background. The Victorian Infectious Diseases Service currently provides telehealth care for rural and regional patients with hepatitis C. From March 2016 direct acting antiviral therapy (DAA) for Hepatitis C has been subsidised for all Australian adults with Hepatitis C. The wide geographic distribution of Australia's population means patients have to travel considerable distances to access specialist care. The increasing availability of web-based videoconferencing platforms have provided unprecedented capacity to manage patients remotely. The primary aim of this study is to determine whether telehealth delivered hepatitis C management achieves virological outcomes comparable to that achieved in randomised clinical trials.
Methods. The study is part of a quality audit of the hepatitis and outreach service. Measured outcomes were; (i) proportion of patients achieving a sustained virological response (SVR); (ii) failure to attend rate (FTA); (iii) frequency of technical difficulties; (iv) patient travel kilometres saved through not attending clinic in person; (v) Reduced carbon production due to reduced travel; and (vi) Consultation duration time.
Results. In 1 year from March 1 , 2016, 58 patients have been commenced on Hepatitis C treatment and managed either partially or completely via telehealth. Of those who have so far completed therapy (29 patients) an SVR rate of 97% has been achieved. Expected SVR genotype 1 (>95%); genotype 3 (>85%). The average travel avoided for each telehealth consultation was 616km and each patient had a
